Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
A common narrative is that high prices are necessary for "orphan drugs" because of the fewer patients. In the context of state health insurance systems, the high prices create significant challenges because of limited budgets.
Year of Publication: 2019
Authors: Aidan Hollis
Journal Title: Healthcare Policy